|
ID
|
Age
|
Ethnicity
|
Race
|
BMI (kg/m2)
|
Diagnosis at Admission
|
Days on Lamotrigine at Baseline Assessment
|
Total Days on Lamotrigine
|
Final Lamotrigine Dose (mg/day)
|
Concurrent Medications
|
|---|
|
1
|
28
|
Non-Hispanic
|
Black
|
26.3
|
EDNOSa
|
−2
|
223
|
150
|
quetiapine XR, bupropion XL, levomilnacipran
|
|
2
|
23
|
Non-Hispanic
|
White
|
20.2
|
EDNOSb
|
−5
|
246
|
200
|
duloxetine, trazodone
|
|
3
|
41
|
Non-Hispanic
|
White
|
21.9
|
EDNOSc
|
−4
|
253
|
100
|
escitalopram
|
|
4
|
42
|
Hispanic
|
Other
|
28.3
|
BN
|
1
|
190
|
100
|
venlafaxine XR, naltrexone
|
|
5
|
18
|
Non-Hispanic
|
White
|
19.7
|
AN-BP
|
1
|
86
|
200
|
sertraline, gabapentin
|
|
6
|
31
|
Non-Hispanic
|
White
|
20.1
|
AN-BP
|
1
|
85
|
200
|
gabapentin, naltrexone
|
|
7
|
25
|
Non-Hispanic
|
White
|
19.1
|
AN-R
|
0
|
102
|
200
|
duloxetine, sertralined
|
|
8
|
31
|
Hispanic
|
Other
|
22.3
|
AN-BP
|
0
|
71
|
100
|
fluoxetine
|
|
9
|
32
|
Non-Hispanic
|
Other
|
25.7
|
BN
|
1
|
71
|
200
|
duloxetine
|
-
aHigh-normal to mildly overweight with restrictive eating and purging; bMildly underweight AN with alternating severe restrictive eating, bingeing, and occasional purging; cLifetime history of mostly BN with episodes of AN-BP. During period of study, most characteristic of low-normal-weight AN-P; dDuloxetine was concurrent with lamotrigine for one month and was subsequently replaced with sertraline in the second month. In the third month, lamotrigine was the only medication prescribed. BMI = body mass index; AN-BP = anorexia nervosa, binge-eating/purging subtype; EDNOS = eating disorder not otherwise specified; BN = bulimia nervosa
